drugset / Trial / NCT04102449
Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast
Phase 4
Withdrawn
Medical University of Graz
Celgene Corporation · collabMedical University Innsbruck · collabMedical University of Vienna · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The main purpose of this study is to validate the ultrasound scores PsASon22 and PsASon13 in patients with active psoriatic arthritis undergoing a treatment with Apremilast.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2022-02
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | Oral |